2+ hour, 28+ min ago  (242+ words) Biosimilar anti-VEGF agents matched the reference ranibizumab in vision outcomes and safety across retinal diseases in India, at a lower cost. Biosimilar anti-VEGF agents matched reference ranibizumab in vision outcomes and safety across retinal diseases in India, at substantially lower…...

4+ mon, 3+ day ago  (250+ words) CHMP backs a fifth teriparatide biosimilar as biosimilars in Europe grow, while US patent fights threaten new biologic competition. The global biosimilar landscape continues to evolve as European regulators expand treatment options for patients with chronic conditions, while legal battles…...

5+ mon, 6+ day ago  (257+ words) New Danish registry data confirm the safety of switching to infliximab biosimilars, showing low rates of serious adverse events in patients with inflammatory arthritis. | Image credit: Ilya - stock. adobe. com During the 1-year follow-up period, serious safety events were infrequent…...

5+ mon, 1+ week ago  (119+ words) In HER2-positive breast cancer, pertuzumab remains a cornerstone therapy, but its price has limited access in some markets, underscoring the need for biosimilar alternatives that can maintain clinical confidence while expanding affordability. 1 A new study confirms KM118, a proposed biosimilar to…...

5+ mon, 3+ week ago  (105+ words) The biosimilar landscape experienced significant expansion in late 2025 and early 2026, marked by crucial regulatory progress in Europe and strategic moves in North America. These developments enhance access to innovative treatments for people living with chronic conditions in immunology, oncology, and…...

6+ mon, 1+ week ago  (140+ words) The momentum in the ustekinumab space continued with the FDA approval of Starjemza (ustekinumab-hmny) in May 2025, marking the eighth ustekinumab biosimilar to receive regulatory clearance. Starjemza, developed through a partnership between Hikma Pharmaceuticals and Bio-Thera Solutions, is approved for treating…...

11+ mon, 2+ week ago  (584+ words) As clinicians in Australia search for alternatives following the loss of subsidized Avastin (reference bevacizumab), many have turned to Mvasi'an oncology-approved biosimilar'using it off-label to manage a wide range of sight-threatening retinal conditions. Now, real-world data from South Australia's public…...

6+ mon, 2+ week ago  (504+ words) The continued expansion of the biosimilar market into ophthalmology is helping to redefine treatment landscapes for serious retinal diseases like neovascular age-related macular degeneration (wet AMD) and diabetic macular edema (DME). The most-read ophthalmology biosimilar stories of 2025 included FDA approvals…...

7+ mon, 2+ week ago  (186+ words) The FDA has granted approval to Poherdy (pertuzumab-dpzb) injection, making it the first biosimilar approved for Perjeta (pertuzumab). Poherdy was also with interchangeability. 1 This approval, granted to the product developed by Shanghai Henlius Biotech and commercialized by Organon, signals the…...

7+ mon, 1+ week ago  (238+ words) November 2025 highlights FDA approvals for denosumab and pertuzumab biosimilars, enhancing competition and access in oncology and bone health markets. November 2025 marked a period of significant activity in the biosimilar market, characterized by multiple FDA approvals and crucial policy discussions concerning…...